ISCT 2021 | Off-the-shelf cell therapy for bone indications: ALLOB & JTA-004

Miguel Forte, MD, PhD, Bone Therapeutics SA, Gosselies, Belgium describes ongoing research investigating allogeneic mesenchymal stromal cell (MSC)-derived osteoblastic cells (ALLOB) for the formation of bone in orthopedic conditions. The safety and efficacy of ALLOB has been tested in patients with degenerative disc disease (NCT02205138) and long bone fractures (NCT02020590), and its impact in tibial fractures is being evaluated in the ongoing Phase IIb ALLOB-TF2 trial (NCT04432389). Dr Forte also describes JTA-004, an intra-articular injectable currently being investigated in patients with knee osteoarthritis (NCT04333160), as well as plans to expand their MSC platform into immunomodulatory conditions. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.